Archive image: Dr. Huzaifa Khorakiwala, Executive Director, Wockardt Ltd
Dr. Huzaifa Khorakiwala, executive director of Wockardt LTD, said on Saturday that the imposition of American reciprocal rates, if they extend to Indian pharmaceutical products, will propose a significant challenge for the industry. “If the tariffs come, it is not an opportunity; it is a challenge, and it is how you address the challenge that is the question,” he said.
The announcement of reciprocal rates of the president of the United States, last week, has sent worldwide tremors, even in India. However, in recent developments, Trump announced on Wednesday a 90 -day break about tariffs against all countries, except China, for negotiating tariffs. He has also said that the United States will soon announce the main rates on pharmaceutical products. Going beyond, Khorakiwala said Wockardt Ltd has become the world leader in antibiotic research, with approved essays.
“The trials are now approved, and we are becoming the world leader in antibiotic research, and the successful product WCK-5222-Zenic has given a success of 97 percent in the phase 3 clinical trial, and we are sure that we follow itrafy itraphy itraphy itraphy itrast.
According to the official data of the Ministry of Chemicals and Fertilizers, the Pharmaceutical Industry of India has gained international recognition such as the “world pharmacy”, particularly for the role of supply in the supply of vaccines, essential medicines and Medicalond. The sector has shown its innovative abilities and has been established as a crucial member of the global pharmaceutical value chain.
Third classification worldwide in pharmaceutical and pharmaceutical production by volume, India exports to approximately 200 countries and territories. The five main destinations for thesis exports are the United States, Belgium, South Africa, the United Kingdom and Brazil.
Posted on April 12, 2025